A Phase I, Single-center, Open-label, 3-group, Fixed-sequence Study to Assess the Effect of Itraconazole, a Potent CYP3A4 Inhibitor, or Diltiazem, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a CYP3A4/CYP3A5 Substrate, in Healthy Young Male and Female Volunteers

Trial Profile

A Phase I, Single-center, Open-label, 3-group, Fixed-sequence Study to Assess the Effect of Itraconazole, a Potent CYP3A4 Inhibitor, or Diltiazem, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a CYP3A4/CYP3A5 Substrate, in Healthy Young Male and Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Lanabecestat (Primary) ; Diltiazem; Itraconazole; Midazolam
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Acronyms AZD3293DDI
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 14 Jan 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 18 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top